Table: q1_q4_2019_prescription_drugs_wac_increases , manufacturer_name like O*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000197	OPKO Pharmaceutucals, LLC	03/31/2019	70301100101	Rayaldee (calcifediol) 30 mcg ER capsules 30 count bottle	01/21/2019	89.00	1082.00	03/14/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	OPKO did not acquire this drug within the last five years.
Rx0000197	OPKO Pharmaceutucals, LLC	03/31/2019	70301100102	Rayaldee (calcifediol) 30 mcg ER capsules 60 count bottle	01/21/2019	178.00	2164.00	03/14/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	OPKO did not acquire this drug within the last five years.
Rx0000067	Otsuka America Pharmaceutical, Inc.	06/30/2019	59148004580	Abilify Maintena 300mg DCS	04/01/2019	81.24	1706.05	10/19/2024	Single Source Drug	None	1	Otsuka is committed to making responsible pricing determinations for our products, including ABILIFY MAINTENA®, and in so doing we consider a range of factors. Otsuka continues to concentrate on areas of unmet medical need in mental health, and cardio-renal. As a general matter, our WAC determinations are influenced by research and development costs (including investments in product and portfolio innovation); manufacturing, distribution, and regulatory costs; market and competitive factors; downstream demands for price concessions/rebates; value to patients and the health care system; and access and affordability. Pricing decisions at Otsuka are made at the executive level in adherence with all federal and state laws. These decisions and underlying considerations are proprietary, and Otsuka does not believe this information is in the public domain or otherwise publicly available. As a result, Otsuka is limiting its response pursuant to Cal. Health and Safety Code § 127679 (b).	None	None	1	None	None	None	None	None	None	None	None	None	None	ABILIFY MAINTENA® was developed by Otsuka.
Rx0000067	Otsuka America Pharmaceutical, Inc.	06/30/2019	59148001871	Abilify Maintena 300mg Kit	04/01/2019	81.24	1706.05	10/19/2024	Single Source Drug	None	1	Otsuka is committed to making responsible pricing determinations for our products, including ABILIFY MAINTENA®, and in so doing we consider a range of factors. Otsuka continues to concentrate on areas of unmet medical need in mental health, and cardio-renal. As a general matter, our WAC determinations are influenced by research and development costs (including investments in product and portfolio innovation); manufacturing, distribution, and regulatory costs; market and competitive factors; downstream demands for price concessions/rebates; value to patients and the health care system; and access and affordability. Pricing decisions at Otsuka are made at the executive level in adherence with all federal and state laws. These decisions and underlying considerations are proprietary, and Otsuka does not believe this information is in the public domain or otherwise publicly available. As a result, Otsuka is limiting its response pursuant to Cal. Health and Safety Code § 127679 (b).	None	None	1	None	None	None	None	None	None	None	None	None	None	ABILIFY MAINTENA® was developed by Otsuka.
Rx0000067	Otsuka America Pharmaceutical, Inc.	06/30/2019	59148007280	Abilify Maintena 400mg DCS	04/01/2019	108.32	2274.73	10/19/2024	Single Source Drug	None	1	Otsuka is committed to making responsible pricing determinations for our products, including ABILIFY MAINTENA®, and in so doing we consider a range of factors. Otsuka continues to concentrate on areas of unmet medical need in mental health, and cardio-renal. As a general matter, our WAC determinations are influenced by research and development costs (including investments in product and portfolio innovation); manufacturing, distribution, and regulatory costs; market and competitive factors; downstream demands for price concessions/rebates; value to patients and the health care system; and access and affordability. Pricing decisions at Otsuka are made at the executive level in adherence with all federal and state laws. These decisions and underlying considerations are proprietary, and Otsuka does not believe this information is in the public domain or otherwise publicly available. As a result, Otsuka is limiting its response pursuant to Cal. Health and Safety Code § 127679 (b).	None	None	1	None	None	None	None	None	None	None	None	None	None	ABILIFY MAINTENA® was developed by Otsuka.
Rx0000067	Otsuka America Pharmaceutical, Inc.	06/30/2019	59148001971	Abilify Maintena 400mg Kit	04/01/2019	108.32	2274.73	10/19/2024	Single Source Drug	None	1	Otsuka is committed to making responsible pricing determinations for our products, including ABILIFY MAINTENA®, and in so doing we consider a range of factors. Otsuka continues to concentrate on areas of unmet medical need in mental health, and cardio-renal. As a general matter, our WAC determinations are influenced by research and development costs (including investments in product and portfolio innovation); manufacturing, distribution, and regulatory costs; market and competitive factors; downstream demands for price concessions/rebates; value to patients and the health care system; and access and affordability. Pricing decisions at Otsuka are made at the executive level in adherence with all federal and state laws. These decisions and underlying considerations are proprietary, and Otsuka does not believe this information is in the public domain or otherwise publicly available. As a result, Otsuka is limiting its response pursuant to Cal. Health and Safety Code § 127679 (b).	None	None	1	None	None	None	None	None	None	None	None	None	None	ABILIFY MAINTENA® was developed by Otsuka.
Rx0000067	Otsuka America Pharmaceutical, Inc.	06/30/2019	59148003513	Rexulti 0.25mg tablets 30 count bottle	04/01/2019	55.47	1164.89	04/12/2026	Single Source Drug	None	1	Otsuka is committed to making responsible pricing determinations for our products, including REXULTI ®, and in so doing we consider a range of factors. Otsuka continues to concentrate on areas of unmet medical need in mental health, and cardio-renal. As a general matter, our WAC determinations are influenced by research and development costs (including investments in product and portfolio innovation); manufacturing, distribution, and regulatory costs; market and competitive factors; downstream demands for price concessions/rebates; value to patients and the health care system; and access and affordability. Pricing decisions at Otsuka are made at the executive level in adherence with all federal and state laws. These decisions and underlying considerations are proprietary, and Otsuka does not believe this information is in the public domain or otherwise publicly available. As a result, Otsuka is limiting its response pursuant to Cal. Health and Safety Code § 127679 (b).	None	None	1	None	None	None	None	None	None	None	None	None	None	REXULTI® was developed by Otsuka. The patent for REXULTI® expires on April 12, 2026 but could be extended to 4Q 2028 if the patent term extension is granted by the US Patent Office.
Rx0000067	Otsuka America Pharmaceutical, Inc.	06/30/2019	59148003613	Rexulti 0.5mg tablets 30 count bottle	04/01/2019	55.47	1164.89	04/12/2026	Single Source Drug	None	1	Otsuka is committed to making responsible pricing determinations for our products, including REXULTI ®, and in so doing we consider a range of factors. Otsuka continues to concentrate on areas of unmet medical need in mental health, and cardio-renal. As a general matter, our WAC determinations are influenced by research and development costs (including investments in product and portfolio innovation); manufacturing, distribution, and regulatory costs; market and competitive factors; downstream demands for price concessions/rebates; value to patients and the health care system; and access and affordability. Pricing decisions at Otsuka are made at the executive level in adherence with all federal and state laws. These decisions and underlying considerations are proprietary, and Otsuka does not believe this information is in the public domain or otherwise publicly available. As a result, Otsuka is limiting its response pursuant to Cal. Health and Safety Code § 127679 (b).	None	None	1	None	None	None	None	None	None	None	None	None	None	REXULTI® was developed by Otsuka. The patent for REXULTI® expires on April 12, 2026 but could be extended to 4Q 2028 if the patent term extension is granted by the US Patent Office.
Rx0000067	Otsuka America Pharmaceutical, Inc.	06/30/2019	59148003713	Rexulti 1mg tablets 30 count bottle	04/01/2019	55.47	1164.89	04/12/2026	Single Source Drug	None	1	Otsuka is committed to making responsible pricing determinations for our products, including REXULTI ®, and in so doing we consider a range of factors. Otsuka continues to concentrate on areas of unmet medical need in mental health, and cardio-renal. As a general matter, our WAC determinations are influenced by research and development costs (including investments in product and portfolio innovation); manufacturing, distribution, and regulatory costs; market and competitive factors; downstream demands for price concessions/rebates; value to patients and the health care system; and access and affordability. Pricing decisions at Otsuka are made at the executive level in adherence with all federal and state laws. These decisions and underlying considerations are proprietary, and Otsuka does not believe this information is in the public domain or otherwise publicly available. As a result, Otsuka is limiting its response pursuant to Cal. Health and Safety Code § 127679 (b).	None	None	1	None	None	None	None	None	None	None	None	None	None	REXULTI® was developed by Otsuka. The patent for REXULTI® expires on April 12, 2026 but could be extended to 4Q 2028 if the patent term extension is granted by the US Patent Office.
Rx0000067	Otsuka America Pharmaceutical, Inc.	06/30/2019	59148003813	Rexulti 2mg tablets 30 count bottle	04/01/2019	55.47	1164.89	04/12/2026	Single Source Drug	None	1	Otsuka is committed to making responsible pricing determinations for our products, including REXULTI ®, and in so doing we consider a range of factors. Otsuka continues to concentrate on areas of unmet medical need in mental health, and cardio-renal. As a general matter, our WAC determinations are influenced by research and development costs (including investments in product and portfolio innovation); manufacturing, distribution, and regulatory costs; market and competitive factors; downstream demands for price concessions/rebates; value to patients and the health care system; and access and affordability. Pricing decisions at Otsuka are made at the executive level in adherence with all federal and state laws. These decisions and underlying considerations are proprietary, and Otsuka does not believe this information is in the public domain or otherwise publicly available. As a result, Otsuka is limiting its response pursuant to Cal. Health and Safety Code § 127679 (b).	None	None	1	None	None	None	None	None	None	None	None	None	None	REXULTI® was developed by Otsuka. The patent for REXULTI® expires on April 12, 2026 but could be extended to 4Q 2028 if the patent term extension is granted by the US Patent Office.
Rx0000067	Otsuka America Pharmaceutical, Inc.	06/30/2019	59148003913	Rexulti 3mg tablets 30 count bottle	04/01/2019	55.47	1164.89	04/12/2026	Single Source Drug	None	1	Otsuka is committed to making responsible pricing determinations for our products, including REXULTI ®, and in so doing we consider a range of factors. Otsuka continues to concentrate on areas of unmet medical need in mental health, and cardio-renal. As a general matter, our WAC determinations are influenced by research and development costs (including investments in product and portfolio innovation); manufacturing, distribution, and regulatory costs; market and competitive factors; downstream demands for price concessions/rebates; value to patients and the health care system; and access and affordability. Pricing decisions at Otsuka are made at the executive level in adherence with all federal and state laws. These decisions and underlying considerations are proprietary, and Otsuka does not believe this information is in the public domain or otherwise publicly available. As a result, Otsuka is limiting its response pursuant to Cal. Health and Safety Code § 127679 (b).	None	None	1	None	None	None	None	None	None	None	None	None	None	REXULTI® was developed by Otsuka. The patent for REXULTI® expires on April 12, 2026 but could be extended to 4Q 2028 if the patent term extension is granted by the US Patent Office.
Rx0000067	Otsuka America Pharmaceutical, Inc.	06/30/2019	59148004013	Rexulti 4mg tablets 30 count bottle	04/01/2019	55.47	1164.89	04/12/2026	Single Source Drug	None	1	Otsuka is committed to making responsible pricing determinations for our products, including REXULTI ®, and in so doing we consider a range of factors. Otsuka continues to concentrate on areas of unmet medical need in mental health, and cardio-renal. As a general matter, our WAC determinations are influenced by research and development costs (including investments in product and portfolio innovation); manufacturing, distribution, and regulatory costs; market and competitive factors; downstream demands for price concessions/rebates; value to patients and the health care system; and access and affordability. Pricing decisions at Otsuka are made at the executive level in adherence with all federal and state laws. These decisions and underlying considerations are proprietary, and Otsuka does not believe this information is in the public domain or otherwise publicly available. As a result, Otsuka is limiting its response pursuant to Cal. Health and Safety Code § 127679 (b).	None	None	1	None	None	None	None	None	None	None	None	None	None	REXULTI® was developed by Otsuka. The patent for REXULTI® expires on April 12, 2026 but could be extended to 4Q 2028 if the patent term extension is granted by the US Patent Office.
Rx0000067	Otsuka America Pharmaceutical, Inc.	03/31/2019	59148002050	Samsca 15mg tablets (blister pack of 10)	01/15/2019	214.67	4507.97	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=50	please see attached document for additional information.
Rx0000067	Otsuka America Pharmaceutical, Inc.	03/31/2019	59148002150	Samsca 30mg tablets (blister pack of 10)	01/15/2019	222.69	4676.49	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=51	please see attached document for additional information